Founded in 1999, Shanghai Serum Bio-technology Co., Ltd. (hereinafter referred to as “Serum Biotech” or “the Company”) is a high-tech biopharmaceutical enterprise. The Company specializes in the R&D, production and commercialization of antitoxin and antiserum products.

Serum Biotech holds a unique position in snakebite treatment with its proprietary equine antivenin series—the only specific antidote for venomous snakebites in China—achieving self-sufficiency in domestic emergency snakebite treatment. Its innovative “next-generation tetanus antitoxin product,” equine anti-tetanus immunoglobulin (F(ab’)₂), significantly reduces the incidence of allergic reactions and serum sickness caused by heterologous protein, compared to conventional therapies. In rabies prevention, the company’s anti-rabies serum product serves as a critical prophylactic intervention.

With these efforts, Serum Biotech is dedicated to sustaining long-term competitiveness and advancing public health outcomes for a broader patient population.